Protective immunization against group B meningococci using anti-idiotypic mimics of the capsular polysaccharide

被引:17
作者
Beninati, C
Arseni, S
Mancuso, G
Magliani, W
Conti, S
Midiri, A
Biondo, C
Polonelli, L
Teti, G
机构
[1] Univ Messina, Dipartimento Patol & Microbiol Sperimentale, Messina, Italy
[2] Univ Parma, Sez Microbiol, Dipartimento Patol, I-43100 Parma, Italy
[3] Univ Parma, Sez Microbiol, Med Lab, I-43100 Parma, Italy
关键词
D O I
10.4049/jimmunol.172.4.2461
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Use of the serogroup B meningococcal capsular polysaccharide (MenB CP) as a vaccine is hampered by the presence of epitopes that cross-react with human polysialic acid. As non-cross-reactive, protective capsular epitopes have also been described, we set out to develop protein mimics of one of such epitopes using as a template a highly protective mAb (mAb Seam 3) raised against a chemically modified form of the MenB CP (N-Pr MenB CP). Using phage display, anti-idiotypic single-chain Ab fragments (scFvs) were obtained from spleen cells of mice immunized with the Seam 3 mAb. Two Seam 3-specific scFvs competed with N-Pr MenB CP for binding to either mAb Seam 3 or rabbit Abs present in typing sera. Moreover, in mice and rabbits the scFvs elicited the production of Abs reacting with both N-Pr MenB CP and whole meningococci, but not with human polysialic acid. These scFv-induced Ab responses were boostable and of the Th1 type, as shown by a predominance of IgG2a. In addition, passive immunization with sera from scFv-immunized animals partially protected neonatal mice from experimental infection with group B meningococci. In conclusion, we have produced anti-idiotypic scFvs that mimic a protective MenB CP epitope and may be useful in the development of an alternative group B meningococcal vaccine. The Journal of Immunology, 2004, 172: 2461-2468.
引用
收藏
页码:2461 / 2468
页数:8
相关论文
共 32 条
[1]
Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus [J].
Agadjanyan, M ;
Luo, P ;
Westerink, MAJ ;
Carey, LA ;
Hutchins, W ;
Steplewski, Z ;
Weiner, DB ;
KieberEmmons, T .
NATURE BIOTECHNOLOGY, 1997, 15 (06) :547-551
[2]
IMMUNOGENICITY OF MENINGOCOCCAL-B POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID OR CRM197 VIA ADIPIC ACID DIHYDRAZIDE [J].
BARTOLONI, A ;
NORELLI, F ;
CECCARINI, C ;
RAPPUOLI, R ;
COSTANTINO, P .
VACCINE, 1995, 13 (05) :463-470
[3]
Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria [J].
Beninati, C ;
Oggioni, MR ;
Boccanera, M ;
Spinosa, MR ;
Maggi, T ;
Conti, S ;
Magliani, W ;
De Bernardis, F ;
Teti, G ;
Cassone, A ;
Pozzi, G ;
Polonelli, L .
NATURE BIOTECHNOLOGY, 2000, 18 (10) :1060-1064
[4]
Beninati Concetta, 2000, Trends in Microbiology, V8, P492, DOI 10.1016/S0966-842X(00)01858-8
[5]
Buchanan RM, 1998, J IMMUNOL, V161, P5525
[6]
Activity and cross-reactivity of antibodies induced in mice by immunization with a group B meningococcal conjugate [J].
Coquillat, D ;
Bruge, J ;
Danve, B ;
Latour, M ;
Hurpin, C ;
Schulz, D ;
Durbec, P ;
Rougon, G .
INFECTION AND IMMUNITY, 2001, 69 (11) :7130-7139
[7]
FINNE J, 1983, LANCET, V2, P355
[8]
FRASCH CE, 1985, REV INFECT DIS, V7, P504
[9]
GLICK MC, 1991, PROG CLIN BIOL RES, V366, P267
[10]
Granoff DM, 1998, J IMMUNOL, V160, P5028